Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Posted: January 13, 2025 at 2:54 am

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024).

Read more:
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Related Posts